

1 **Title: Does susceptibility to novel coronavirus (COVID-19) infection**  
2 **differ by age?: Insights from mathematical modelling**

3 **Authors:** Ryosuke Omori<sup>1</sup>, Ryota Matsuyama<sup>2</sup>, Yukihiro Nakata<sup>3</sup>

4 **Affiliations:**

5 <sup>1</sup> Research Center for Zoonosis Control, Hokkaido University, Kita-ku, Sapporo-shi,  
6 Hokkaido 001-0020, Japan

7 <sup>2</sup> Graduate School of Biomedical and Health Sciences, Hiroshima University

8 <sup>3</sup> Department of Physics and Mathematics, Aoyama Gakuin University

9 (Correspondence to Ryosuke Omori at: Address: Kita-20 Nishi-10, Kita-Ku, Sapporo,  
10 001-0020, Japan; Tel: +81-11-706-9488, Fax: +81-11-706-9491; Email:  
11 omori@czc.hokudai.ac.jp)

12

13

14

15 **Abstract**

16 Among Italy, Spain, and Japan, the age distributions of novel coronavirus (COVID-19)  
17 mortality show only small variation even though the number of deaths per country  
18 shows large variation. To understand the determinant for this situation, we constructed a  
19 mathematical model describing the transmission dynamics and natural history of  
20 COVID-19 and analyzed the dataset of fatal cases of COVID-19 in Italy, Spain, and  
21 Japan. We estimated the parameter which describes the age-dependency of  
22 susceptibility by fitting the model to reported data, taking into account the effect of  
23 change in contact patterns during the outbreak of COVID-19, and the fraction of  
24 symptomatic COVID-19 infections. Our modelling study revealed that if the mortality  
25 rate or the fraction of symptomatic infections among all COVID-19 cases does not  
26 depend on age, then unrealistically different age-dependencies of susceptibilities against  
27 COVID-19 infections between Italy, Japan, and Spain are required to explain the similar  
28 age distribution of mortality but different basic reproduction numbers ( $R_0$ ). Variation of  
29 susceptibility by age itself cannot explain the robust age distribution in mortality by  
30 COVID-19 in those three countries, however it does suggest that the age-dependencies  
31 of i) the mortality rate and ii) the fraction of symptomatic infections among all COVID-  
32 19 cases determine the age distribution of mortality by COVID-19.

### 33 **Introduction**

34           Since its emergence, coronavirus disease 2019 (COVID-19) has resulted in a  
35   pandemic and has produced a huge number of cases worldwide (World Health  
36   Organization, 2020). As of May 29, 2020, the number of confirmed cases in Italy was  
37   231,139, with 237,141 in Spain, and 16,683 in Japan (World Health Organization,  
38   2020). Of those infected, it has been reported that elderly individuals account for a large  
39   portion of fatal cases inducing a large heterogeneity in the age distribution of mortality  
40   (Dowd et al., 2020; Onder et al., 2020; Wu et al., 2020).

41           The expected value of mortality (the number of deaths, hereafter referred to as  
42   mortality) is calculated as the product of the number of cases and the mortality rate  
43   among cases (hereafter referred to as mortality rate). As the background mechanism of  
44   the heterogeneity of mortality by age, the association of two epidemiological factors  
45   with mortality can be considered: i) the age-dependency of susceptibility to infection,  
46   which is related to the heterogeneity in the number of cases, and ii) the age-dependency  
47   of severity, which is related to the heterogeneity in the mortality rate, e.g. the rate of  
48   becoming symptomatic, severe, or fatal case among infected individuals. For the first  
49   factor, a high susceptibility for infection will generate a larger number of infections and  
50   result in an increase in fatal cases. The possibility of heterogeneity in susceptibility by

51 age was pointed out by the analysis of epidemiological data reported from Wuhan,  
52 China (Lee et al., 2020; Wu et al., 2020; Zhang et al., 2020) and from Iceland  
53 (Gudbjartsson, 2020). For the second factor, an increase in severity will result in a  
54 higher mortality rate and subsequently a rise in the number of fatal cases. This  
55 assumption is also reasonable because elder age as well as the existence of  
56 comorbidities, which are likely with aging, have been reported as risk factors for severe  
57 COVID-19 infections (Bonanad et al., 2020; Guan et al., 2020; Liu et al., 2020; Shi et  
58 al., 2020; Verity et al., 2020; Zhou et al., 2020). Although not yet shown in relation to  
59 severe acute respiratory syndrome corona virus 2 (SARS Cov-2), which is the causal  
60 agent of COVID-19, the presence of age-dependent enhancement of severity has been  
61 suggested in SARS coronavirus by the analysis of the innate immune responses in the  
62 BALB/c mouse model (Baas et al., 2008; Chen et al., 2010; Roberts et al., 2005).  
63 Additionally, it has been suggested that antibody-dependent enhancement (ADE) can  
64 contribute to the formation of the observed age-dependency of severity, as suggested in  
65 SARS and Middle East respiratory syndrome (MERS) cases (Arabi et al., 2016; Drosten  
66 et al., 2014; Tay et al., 2020; Tetro, 2020; Wan et al., 2018; Yang et al., 2005).

67 Interestingly, the age distribution of mortality by COVID-19 (the distribution of  
68 the proportion of deaths per age group among all deaths), is similar between Italy,

69 Japan, and Spain, even though the number of deaths are quite different among them  
70 (Ministry of Health, Labor and Welfare, 2020; Epicentro, Istituto Superiore di Sanità,  
71 2020; Centro de Coordinación de Alertas y Emergencias Sanitarias, 2020). The large  
72 difference in the number of deaths between the countries suggests a large difference in  
73 their basic reproduction numbers,  $R_0$ s. An independency between age distribution of  
74 mortality by COVID-19 and  $R_0$  is suggested. From this independency of age  
75 distributions of mortality from  $R_0$ , it can be expected that the contribution of  
76 heterogeneity in susceptibility by age to forming the age distribution of mortality is  
77 small. That is because, as we will show in this paper, though the age-dependency of  
78 severity will naturally produce a proportional effect on the distribution of mortality and  
79 result in the formation of robust distributions, when the age-dependency of  
80 susceptibility forms the age distribution of mortality, the age distribution of mortality  
81 highly depends on  $R_0$  and shows variability.

82 To understand the background of robust age distribution of mortality with varied  
83  $R_0$ , we constructed a mathematical model describing the transmission dynamics of  
84 COVID-19 and analyzed the impact of age-dependent susceptibility on the age  
85 distribution of mortality. The heterogeneity in social contacts by age may also  
86 contribute to the age distribution of mortality. Our model took into account the

87 heterogeneity in social contacts by age and country, and the effect of behavioral change  
88 outside of the household during the outbreak. We also estimated and compared the age-  
89 dependent susceptibility in Japan, Italy, and Spain to argue the existence of  
90 heterogeneity in susceptibility among age groups.

91

## 92 **Results**

93 Our result shows variation of susceptibility among age groups measured by the  
94 exponent parameter  $\varphi$  can explain the age distribution of mortality by COVID-19  
95 (figure 2(a)). However, the age distribution of mortality formed by the age-dependency  
96 of susceptibility is influenced by the value of  $R_0$  (figure 2(b)), which cannot explain the  
97 similarity in age distributions of mortality among Italy, Japan, and Spain. On the other  
98 hand, if susceptibility is constant among age groups, the impact of  $R_0$  is quite small on  
99 the age distribution of mortality (figure 3).

100 Assuming that the age-dependency of mortality by COVID-19 is determined by  
101 only age-dependent susceptibility, i.e., the mortality rate does not depend on age, the  
102 exponent parameter,  $\varphi$ , describing the variation of susceptibility among age groups for  
103 each country, Italy, Japan, and Spain, was estimated as shown in figure 4. From the  
104 difference of the  $R_0$  value and country, the estimated value of  $\varphi$  is largely varied. The

105 impact of reductions in contacts outside of the household on the estimated value of  $\varphi$   
106 was small. The estimate of  $\varphi$  in Italy, assuming a range of  $R_0 = 2.4-3.3$  (Zhuang et al.,  
107 2020; D'Arienzo and Coniglio, 2020) was 15.0 (95% CI = 14.0-16.0), 16.3 (95% CI =  
108 14.9-17.7), and 16.9 (95% CI = 15.4-18.4) for 80%, 40%, and no reduction in contacts  
109 outside of the household. For Japan, the estimate of  $\varphi$  assuming  $R_0 = 1.7$  (Expert  
110 Meeting on the Novel Coronavirus Disease Control, 2020) was 4.2 (95%CI = 3.7-4.9),  
111 5.5 (95%CI = 4.9-6.3), and 6.1 (95%CI = 5.4-6.9) for 80%, 40%, and no reduction in  
112 contacts outside of the household. When it comes to Spain, the estimate of  $\varphi$  assuming  
113 an  $R_0 = 2.9$  (Caicedo-Ochoa et al., 2020) was 10.5 (95%CI = 10.4-10.6), 11.7 (95%CI =  
114 11.6-11.9), and 12.3 (95%CI = 12.2-12.5) for 80%, 40%, and no reduction in contacts  
115 outside of the household.

116 The estimates of  $\varphi$ , assuming that the fraction of infections becoming  
117 symptomatic does not depend on age, were also varied by the value of  $R_0$  and by  
118 country (figure 5, 6 and 7). Employing the same assumptions of  $R_0$  value, the estimate  
119 of  $\varphi$  in Italy was 4.8 (95% CI = 4.2-5.3), 5.4 (95% CI = 4.9-5.9), and 5.7 (95% CI = 5.1-  
120 6.2) for 80%, 40%, and no reduction in contacts outside of the household. For Japan, the  
121 estimate of  $\varphi$  was 0.0 (95%CI = 0.0-0.9), 0.0 (95%CI = 0.0-1.1), and 0.0 (95%CI = 0.0-  
122 1.2) for 80%, 40%, and no reduction in contacts outside of the household. For Spain, the

123 estimate of  $\varphi$  was 1.7 (95%CI = 1.4-1.9), 2.2 (95%CI = 1.9-2.5), and 2.5 (95%CI = 2.1-  
124 2.8) for 80%, 40%, and no reduction in contacts outside of the household.

125

## 126 **Discussion**

127 In the present study, we explored the role of susceptibility to COVID-19 in  
128 explaining the age distribution of mortality by COVID-19. Interestingly, the age  
129 distributions of mortality from COVID-19 are quite similar between Italy, Japan, and  
130 Spain (figure 1). When comparing the age distributions of mortality, only the  
131 comparison between Italy and Spain is significant ( $p < 0.05$  in Wilcoxon rank sum test  
132 with Bonferroni correction). On the other hand, the numbers of deaths are quite  
133 different (29,525 for Italy, 400 for Japan, 18,818 for Spain). Indeed,  $R_0$  values are  
134 largely different: 2.4-3.3 for Italy (Zhuang et al., 2020; D'Arienzo and Coniglio, 2020),  
135 1.7 for Japan (Expert Meeting on the Novel Coronavirus Disease Control, 2020), and  
136 2.9 for Spain (Caicedo-Ochoa et al., 2020). If the variation of mortality by age is  
137 determined by only the age-dependency of susceptibility, the age distribution of  
138 mortality is affected by  $R_0$  as shown in figure 2(b). However, we observed a similarity  
139 in age distributions of mortalities between Italy, Japan, and Spain where their  $R_0$ s are  
140 quite different. Indeed, unrealistically different  $\varphi$ s among these three countries are



141 required to explain their age distribution of mortality for both settings, i) age-  
142 independent mortality, and, ii) the fraction of infections that becomes symptomatic  
143 among all COVID-19 cases,  $f_s$ , does not depend on age. Although we cannot fully reject  
144 the existence of age-dependency in susceptibility, our results suggest that it does not  
145 largely depend on age, but rather that age-dependency in severity highly contributes to  
146 the formation of the observed age distribution in mortality.

147       The estimates of  $\varphi$ s assuming age independency in symptomatic infections were  
148 smaller than those that assumed age independency in mortality. This suggests that the  
149 age-dependency of the confirmed case fatality rate (cCFR), which can be biased by the  
150 age-dependent difference of the fraction of symptomatic infections among all cases,  
151 partially explains the age distribution in mortality. Indeed, when we assumed that the  
152 fraction of symptomatic infections was not dependent on age, the estimate of  $\varphi$  in Japan  
153 was close to zero in all scenarios regarding the fraction of symptomatic infections,  
154 meaning that susceptibility is constant among age groups (figure 5). Although we  
155 observed  $\varphi$ s around 5 in Italy and 2 in Spain, this does not mean straightforwardly that  
156 susceptibility is age dependent because there is room for an alternative explanation: not  
157 susceptibility, but an age-dependent fraction of symptomatic infections can explain this  
158 age-dependency. Unfortunately, as we do not yet have detailed data regarding the age-

159 dependent fraction of symptomatic infections and the rate of diagnosis in COVID-19,  
160 we cannot conclude which factors (i.e., susceptibility or the fraction of symptomatic  
161 infection among all cases) contributed to the observed age-dependency.

162 Wu et al. (2020) showed variation of susceptibility to symptomatic infection by  
163 age. This susceptibility can be expressed as the product of the susceptibility and the  
164 fraction of symptomatic infection among all cases. To accurately understand  
165 susceptibility (i.e., without the constraint of the symptom onset), estimates of the age-  
166 dependent fraction of symptomatic infections is required.

167 To understand the mechanism of age-dependency of mortality by COVID-19, an  
168 accurate age-dependent mortality rate is required. To estimate the age-dependent  
169 mortality rate, an accurate estimate of the case fatality rate is required. However, the  
170 number of cases, which is the denominator of the case fatality rate, is difficult to  
171 estimate for COVID-19 due to changes in the testing rate (Gostic et al., 2020a; Gostic et  
172 al., 2020b; Omori et al. 2020), the change of case definition (Tsang et al. 2020),  
173 selection biases (Bar-on et al., 2020), and the delay between the onset of symptoms and  
174 death (Linton et al., 2020; Shim et al., 2020; Sun et al., 2020; Verity et al., 2020) as  
175 were the cases we experienced in the surveillance of other emerging diseases (Ghani et  
176 al., 2005; Garske et al., 2008). To address this problem, implementation of active

177 epidemiological surveillances, such as a large-scale cohort study including real-time

178 detection of infections, should be considered.

179           From the modelling perspective on mortality by Covid-19, age-dependency of  
180 severity should be carefully taken into consideration. In particular, in the mathematical  
181 models of ADE, the previous models employed three types of assumptions (Woodall  
182 and Adams, 2014), the assumption of: increasing susceptibility to infection (Recker et  
183 al., 2009; Tang et al., 2018), increasing transmissibility once infection occurred  
184 (Ferguson et al., 1999; Ferguson and Andreasen, 2002; Recker et al., 2009), and  
185 increasing severity and/or mortality associated with infection (Kawaguchi et al., 2003).

186 Based on our results and from the biological/epidemiological observations of past  
187 SARS and MERS cases, the “increasing severity” assumption should be taken into  
188 account when analyzing SARS Cov-2 epidemics.

189           In conclusion, the contribution of age-dependency to susceptibility is difficult to  
190 use to explain the robust age distribution in mortalities by COVID-19, and it suggests  
191 that the age-dependencies of the mortality rate and the fraction of symptomatic  
192 infections among all COVID-19 cases determine the age distribution in mortality from  
193 COVID-19. Further investigations regarding age-dependency on the fraction of

194 infections becoming symptomatic is required to understand the mechanism behind the  
195 mortality by COVID-19 infections.

196

## 197 **Methods**

### 198 **1. Data**

199 We analyzed the number of mortalities caused by COVID-19 in Italy reported  
200 on 13th May 2020, Japan reported on 7th May 2020, and Spain reported on 12th May  
201 2020. The data were collected from public data sources in each country (Ministry of  
202 Health, Labor and Welfare, 2020; Epicentro, Istituto Superiore di Sanità, 2020; Centro  
203 de Coordinación de Alertas y Emergencias Sanitarias, 2020).

204

### 205 **2. Model**

206 To understand the background of robust age distribution of mortality with varied  
207  $R_0$ , we employed a mathematical model describing transmissions of COVID-19, an age-  
208 structured SEIR model, which can be written as;

$$209 \quad S'_n = -\beta\sigma_n S_n (\sum_m k_{n,m} I_m), \quad (1)$$

$$210 \quad E'_n = \beta\sigma_n S_n (\sum_m k_{n,m} I_m) - \varepsilon E_n, \quad (2)$$

211 
$$I'_n = \varepsilon E_n - (\gamma + \delta_n)I_n, \quad (3)$$

212 
$$R'_n = \gamma I_n, \quad (4)$$

213 
$$D'_n = \delta_n I_n, \quad (5)$$

214 where  $S_n$ ,  $E_n$ ,  $I_n$ ,  $R_n$  and  $D_n$  represent the proportion of susceptible, latent, infectious,  
215 recovered and dead among the entire population, and the subscript index  $n$  denotes age  
216 group. We stratified the entire population by into eight groups,  $n = 1, 2, 3, 4, 5, 6, 7$ , and  
217 8 for < 10 years old (yo), 10-19 yo, 20-29 yo, 30-39 yo, 40-49 yo, 50-59 yo, 60-69 yo,  
218 and 70+ yo.  $\beta$ ,  $k_{n,m}$ ,  $\varepsilon$ ,  $\gamma$  and  $\delta_n$  represent a transmission coefficient, an element of the  
219 contact matrix between age group  $n$  and  $m$ , the progression rate from latent to  
220 infectious, recovery rate and mortality rate among age group  $n$ , respectively.  $\sigma_n$  denotes  
221 the susceptibility of age group  $n$ . For the sake of simplicity, births and deaths by other  
222 than COVID-19 were ignored. To take into account the effect of behavioral changes  
223 outside of the household during the outbreak,  $k_{n,m}$  is decomposed by a matrix for  
224 contacts within household  $k_{in,n,m}$  and that for contacts outside the household  $k_{out,n,m}$ ;

225 
$$k_{n,m} = k_{in,n,m} + \alpha k_{out,n,m}, \quad (6)$$

226 where  $\alpha$  denotes the reduced fraction of contacts outside of the household. We modelled  
227 age specific susceptibility as

228 
$$\sigma_n = cn^\varphi. \quad (7)$$

229 Where  $c$  is a constant among all age groups,  $\varphi$  denotes the exponent parameter  
230 describing the variation of susceptibility among age groups. An increase in  $\varphi$  means an  
231 increase in the variation of susceptibility among age groups, and  $\varphi=0$  means that  
232 susceptibility is equal among all age groups

233

234 **3. Parameterizations**

235 We parameterized  $\varepsilon$  and  $\gamma$  using the values from a previous modelling study of COVID-  
236 19 (Prem et al., 2020). We referred to the contact matrices for Italy, Japan, and Spain  
237 from Prem et al. (Prem et al., 2017).  $\beta$  and  $c$  were controlled such that the basic  
238 reproduction number,  $R_0$ , becomes arbitral values.  $R_0$  was calculated by constructing a  
239 next generation matrix (Diekman and Heesterbeek, 2000; Mossong et al., 2008) using  
240 each country's demographic data obtained from a public data source (United Nations,  
241 2020).

242

#### 243 4. Fitting

244 We calculated the proportions of deaths in the age group  $n$  among all deaths,  $d_n$   
245 ( $= D_n(\infty) / \sum_n D_n(\infty)$ ), and fitted them to the observed data in each country. The  
246 mortality rate among age group  $n$ ,  $\delta_n$ , is required to calculate  $d_n$ , however, a reliable  
247 estimate of  $\delta_n$  for COVID-19 is difficult to obtain. Due to the uncertainty of the fraction  
248 of symptomatic infections per age group,  $\delta_n$  is difficult to estimate from observed data,  
249 i.e., the confirmed case fatality rate among age group  $n$  ( $cCFR_n$ ). Since an estimate of  $\delta_n$   
250 is difficult to obtain, we employed two different settings to calculate  $d_n$ , i)  $\delta_n$  is assumed  
251 to be a constant among all age groups, or, ii)  $\delta_n$  is calculated from  $cCFR_n$  assuming that  
252 the fraction of symptomatic infections among all COVID-19 cases ( $f_s$ ) is not dependent  
253 with age.

254 In setting i), the value of  $\delta_n$  is not required to estimate  $d_n$  once the value of  $R_0$  is  
255 given. We calculated  $d_n$  by calculating the proportions of recovered persons per age  
256 group among all recovered persons  $R_n(\infty) / \sum_n R_n(\infty)$  instead of  $D_n(\infty) / \sum_n D_n(\infty)$ .  
257 In our model, shown in equation (1)-(4),  $R_n(\infty) / \sum_n R_n(\infty)$  is determined by the value  
258 of  $R_0$  completely when all parameter values other than  $\beta$  and  $\delta_n$  are fixed, and

259  $D_n(\infty)/\sum_n D_n(\infty) = R_n(\infty)/\sum_n R_n(\infty)$  if  $\delta_n \neq 0$ . The proof can be found in  
260 supplementary file 1.

261 The assumption in setting i),  $\delta_n$  is constant among all age groups, may be too  
262 strong for the COVID-19 epidemic. To take into account the age-dependency of  
263 mortality by COVID-19,  $\delta_n$  was calculated from the  $cCFR_n$  assuming that  $f_s$  is not  
264 dependent with age. As for the setting ii), assuming three scenarios;  $f_s = 0.05, 0.25,$  and  
265  $0.5,$   $\delta_n$  for each country were calculated using  $cCFR_n$  in each country. We obtained  $\delta_n$   
266 by solving  $cCFR_n = \delta_n/[f_s (\delta_n+\gamma)]$ .

267 We solved the model shown in equations (1)-(5) numerically, and  $d_n$  was  
268 calculated after sufficient time was given to finish the epidemics. We estimated  $\varphi$  using  
269 a log likelihood function describing the multinomial sampling process of deaths per age  
270 group;

$$271 \quad \sum_n D_n \log[d_n(\varphi)]. \quad (8)$$

272 Maximum likelihood estimates of  $\varphi$  with given  $R_0$  were obtained by maximizing  
273 equation (8) and the profile likelihood-based confidence intervals were computed.

274

## 275 **Acknowledgement**

276 The authors gratefully acknowledge the manuscript language review of Dr Heidi L.

277 Gurung.

## 278 **Competing interests**

279 The authors declare no conflicts of interest.

280 **Funding source**

281 R.O. acknowledges support from the Japan Society for the Promotion of Science (JSPS)  
282 Grant-in-Aid for Young Scientists 19K20393. Y.N. was supported by JSPS Grant-in-  
283 Aid for Young Scientists (B) 16K20976. The funders had no role in study design, data  
284 collection and analysis, decision to publish, or preparation of the manuscript.

285 **Ethical approval**

286 This study was based on publicly available data and did not require ethical approval.

287

288 **References**

- 289 1. World Health Organization. Coronavirus disease (COVID-2019) situation reports -  
290 130. Available at: [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)  
291 2019/situation-reports. (Accessed 29th May 2020)
- 292 2. Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, Liu Y, Mills MC.  
293 Demographic science aids in understanding the spread and fatality rates of COVID-  
294 19. *Proc Natl Acad Sci.* 2020; 117(18):9696-9698. doi:10.1073/pnas.2004911117.
- 295 3. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients  
296 Dying in Relation to COVID-19 in Italy. *JAMA.* 2020;323:1775-1776.  
297 doi:10.1001/jama.2020.4683
- 298 4. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, Cowling BJ,  
299 Lipsitch M, Leung GM. Estimating clinical severity of COVID-19 from the



- 300 transmission dynamics in Wuhan, China. *Nat Med.* 2020;26:506-510.  
301 doi:10.1038/s41591-020-0822-7
- 302 5. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to  
303 COVID-19?. *J Microbiol Immunol Infect.* 2020;S1684-1182(20)30039-6.  
304 doi:10.1016/j.jmii.2020.02.011
- 305 6. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, Akdis CA, Gao Y. Clinical  
306 characteristics of 140 patients infected with SARS - CoV - 2 in Wuhan, China.  
307 *Allergy.* 2020;0:1-12. doi:10.1111/all.14238
- 308 7. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl  
309 GL, Saemundsdottir J, Sigurdsson A, Sulem P, Agustsdottir AB, Eiriksdottir B,  
310 Fridriksdottir R, Gardarsdottir EE, Georgsson G, Gretarsdottir OS, Gudmundsson  
311 KR, Gunnarsdottir TR, Gylfason A, Holm H, Jensson BO, Jonasdottir A, Jonsson  
312 F, Josefsdottir KS, Kristjansson T, Magnusdottir DN, le Roux L, Sigmundsdottir G,  
313 Sveinbjornsson G, Sveinsdottir KE, Sveinsdottir M, Thorarensen EA,  
314 Thorbjornsson B, Löve A, Masson G, Jonsdottir I, Möller AD, Gudnason T,  
315 Kristinsson KG, Thorsteinsdottir U, Stefansson K. Spread of SARS-CoV-2 in the  
316 Icelandic Population. *N Engl J Med.* 2020;NEJMoa2006100.  
317 doi:10.1056/NEJMoa2006100.
- 318 8. Bonanad C, García-Blasabe S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-  
319 González V, Fácila L, Ariza A, Núñez J, Cordero A. The effect of age on mortality  
320 in patients with Covid-19: a metanalysis with 611,583 subjects. *J Am Med Dir*  
321 *Assoc.* 2020;In Press. doi:10.1016/j.jamda.2020.05.045
- 322 9. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui  
323 DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY,  
324 Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P,  
325 Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong

- 326 NS. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics  
327 of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720.  
328 doi: 10.1056/NEJMoa2002032.
- 329 10. Liu k, Chen Y, Lin R, Han K., Clinical features of COVID-19 in elderly patients: A  
330 comparison with young and middle-aged patients. *J Infect*. 2020;80(6): e14-e18.  
331 doi:10.1016/j.jinf.2020.03.005
- 332 11. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe  
333 COVID-19 and establishment of a host risk score: findings of 487 cases outside  
334 Wuhan. *Crit Care*. 2020;24(1):108. doi:10.1186/s13054-020-2833-7.
- 335 12. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-  
336 Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin  
337 M, Bhatia S, Boonyasiri A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green  
338 W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S,  
339 Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM.  
340 Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The*  
341 *Lancet Infectious Diseases*. 2020;30:S1473-3099(20)30243-7. doi:10.1016/S1473-  
342 3099(20)30243-7
- 343 13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan  
344 L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and  
345 risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a  
346 retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062.  
347 doi:10.1016/S0140-6736(20)30566-3.
- 348 14. Baas T, Roberts A, Teal TH, Vogel L, Chen J, Tumpey TM, Katze MG, Subbarao  
349 K. Genomic analysis reveals age-dependent innate immune responses to severe  
350 acute respiratory syndrome coronavirus. *J Virol*. 2008;82(19):9465-76. doi:  
351 10.1128/JVI.00489-08
- 352 15. Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, Subbarao K.  
353 Cellular immune responses to severe acute respiratory syndrome coronavirus

- 354 (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in  
355 control of SARS-CoV infection. *J Virol.* 2010;84(3):1289-301.  
356 doi:10.1128/JVI.01281-09
- 357 16. Roberts A, Paddock C, Vogel L, Butler E, Zaki S, Subbarao K. Aged BALB/c mice  
358 as a model for increased severity of severe acute respiratory syndrome in elderly  
359 humans. *J Virol.* 2005;79(9):5833-8. doi:10.1128/JVI.79.9.5833-5838.2005
- 360 17. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A,  
361 Al-Qahtani S, Al-Omari A, Al-Hameed F, Hayden FG, Fowler R, Bouchama A,  
362 Shindo N, Al-Khairy K, Carson G, Taha Y, Sadat M, Alahmadi M. Feasibility of  
363 Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi  
364 Arabia. *Emerg Infect Dis.* 2016;22(9):1554-61. doi:10.3201/eid2209
- 365 18. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M, Hossain R, Madani H,  
366 Sieberg A, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Hajomar W, Albarrak  
367 AM, Al-Tawfiq JA, Zumla AI, Memish ZA. Transmission of MERS-coronavirus in  
368 household contacts. *N Engl J Med.* 2014;371(9):828-35.  
369 doi:10.1056/NEJMoa1405858
- 370 19. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19:  
371 immunity, inflammation and intervention. *Nat Rev Immunol.* 2020;20(6):363-374.  
372 doi:10.1038/s41577-020-0311-8
- 373 20. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? *Microbes Infect.*  
374 2020;22(2):72-73. doi:10.1016/j.micinf.2020.02.006
- 375 21. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, Zhou  
376 Y, Du L, Li F. Molecular Mechanism for Antibody-Dependent Enhancement of  
377 Coronavirus Entry. *J Virol.* 2020;94(5):e02015-19. doi:10.1128/JVI.02015-19.
- 378 22. Yang ZY, Werner HC, Kong WP, Leung K, Traggiai E, Lanzavecchia A, Nabel GJ.  
379 Evasion of antibody neutralization in emerging severe acute respiratory syndrome

- 380 coronaviruses. Proc Natl Acad Sci. 2005;102(3):797-801.  
381 doi:10.1073/pnas.0409065102
- 382 23. Ministry of Health, Labour and Welfare, Japan. Documents for press release. –  
383 Available at <https://www.mhlw.go.jp/content/10906000/000628510.pdf>. (In  
384 Japanese, accessed on 13th May 2020)
- 385 24. EpiCentro, Istituto Superiore di Sanità. Infographic available in English - 13 may  
386 2020 update in COVID-19 integrated surveillance: key national data. Available at  
387 <https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-integrated-surveillance-data>.  
388 (Accessed on 13th May 2020)
- 389 25. Centro de Coordinación de Alertas y Emergencias Sanitarias. Actualización nº 103.  
390 Enfermedad por el coronavirus (COVID-19). 12.05.2020. Available at  
391 [https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_103_COVID-19.pdf)  
392 [China/documentos/Actualizacion\\_103\\_COVID-19.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_103_COVID-19.pdf). (In Spanish, accessed 13th  
393 May 2020)
- 394 26. Zhuang Z, Zhao S, Lin Q, Cao P, Lou Y, Yang L, Yang S, He D, Xiao L.  
395 Preliminary estimates of the reproduction number of the coronavirus disease  
396 (COVID-19) outbreak in Republic of Korea and Italy by 5 March 2020. Int J Infect  
397 Dis. 2020;95:308-310. doi:10.1016/j.ijid.2020.04.044
- 398 27. D'Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction  
399 number, R0, based on the early phase of COVID-19 outbreak in Italy. Biosafety  
400 and Health. 2020;In Press. doi:10.1016/j.bsheal.2020.03.004
- 401 28. Expert Meeting on the Novel Coronavirus Disease Control. The minutes of the fifth  
402 meeting. 2020 March 2. Available at:  
403 [https://www.kantei.go.jp/jp/singi/novel\\_coronavirus/senmonkakaigi/sidai\\_r020302.](https://www.kantei.go.jp/jp/singi/novel_coronavirus/senmonkakaigi/sidai_r020302.pdf)  
404 [pdf](https://www.kantei.go.jp/jp/singi/novel_coronavirus/senmonkakaigi/sidai_r020302.pdf). (In Japanese, accessed 13th May 2020)
- 405 29. Caicedo-Ochoa Y, Rebellón-Sánchez DE, Peñaloza-Rallón M, Cortés-Motta HF,  
406 Méndez-Fandiño YR. Effective Reproductive Number Estimation for Initial Stage  
407 of COVID-19 Pandemic in Latin American Countries. Int J infect Dis.  
408 2020;95:316-318. doi:10.1016/j.ijid.2020.04.069
- 409 30. Gostic K, Gomez ACR, Kucharski AJ, Lloyd-Smith JO. Effectiveness of traveller  
410 screening for emerging pathogens is shaped by epidemiology and natural history of  
411 infection. Elife. 2020; 2015;4: e05564. doi: 10.7554/eLife.05564
- 412 31. Gostic K, Gomez ACR, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated  
413 effectiveness of symptom and risk screening to prevent the spread of COVID-19.  
414 Elife. 2020; 9. doi: 10.7554/eLife.55570

- 415 32. Omori R, Mizumoto K, Chowell G. Changes in testing rates could mask the novel  
416 coronavirus disease (COVID-19) growth rate. *Int J Infect Dis.* 2020;94:116-118.  
417 doi:10.1016/j.ijid.2020.04.021
- 418 33. Tsang TK, Wu P, Lin Y, Lau EH, Leung GM, Cowling BJ. Effect of changing case  
419 definitions for COVID-19 on the epidemic curve and transmission parameters in  
420 mainland China: a modelling study. *Lancet Public Health.* 2020; 5; 5; e289-e296.  
421 doi:10.1016/S2468-2667(20)30089-X.
- 422 34. Bar-on YM, Flamholz A, Phillips R, and Milo R. SARSCoV-2 (COVID-19) by the  
423 numbers. *Elife.* 2020;9:e57309. doi: 10.7554/eLife.57309
- 424 35. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan  
425 B, Kinoshita R, Nishiura H. Incubation Period and Other Epidemiological  
426 Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A  
427 Statistical Analysis of Publicly Available Case Data. *J Clin Med.* 2020;9(2):538.  
428 doi:10.3390/jcm9020538
- 429 36. Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity  
430 of COVID-19 in South Korea. *Int J Infect Dis.* 2020;93:339-344. doi:  
431 10.1016/j.ijid.2020.03.031
- 432 37. Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus  
433 disease 2019 outbreak based on crowdsourced data: a population-level  
434 observational study. *Lancet Digital Health.* 2020;2:e201–e208. doi:10.1016/S2589-  
435 7500(20)30026-1
- 436 38. Ghani AC, Donnelly CA, Cox DR, Griffin JT, Fraser C, Lam TH, Ho LM, Chan  
437 WS, Anderson RM, Hedley AJ, Leung GM. Methods for estimating the case  
438 fatality ratio for a novel, emerging infectious disease. *Am J Epidemiol.*  
439 2005;162:479-486. doi:10.1093/aje/kwi230
- 440 39. Garske T, Legrand J, Donnelly CA, Ward H, Cauchemez S, Fraser C, Ferguson  
441 NM, Ghani AC. Assessing the severity of the novel influenza A/H1N1 pandemic.  
442 *BMJ.* 2008;339;b2840. doi: 10.1136/bmj.b2840
- 443 40. Woodall H, Adams B. Partial cross-enhancement in models for dengue  
444 epidemiology. *J Theor Biol.* 2014;351:67-73. doi: 10.1016/j.jtbi.2014.02.016
- 445 41. Recker M, Blyuss KB, Simmons CP, Hien TT, Wills B, Farrar J, Gupta S.  
446 Immunological serotype interactions and their effect on the epidemiological pattern  
447 of dengue. *Proc Biol Sci.* 2009 Jul 22;276(1667):2541-8. doi:

- 448 10.1098/rspb.2009.0331. Epub 2009 Apr 15. PMID: 19369266; PMCID:  
449 PMC2684681.
- 450 42. Tang B, Huo X, Xiao Y, Ruan S, Wu J. A conceptual model for optimizing vaccine  
451 coverage to reduce vector-borne infections in the presence of antibody-dependent  
452 enhancement. *Theor Biol Med Model*. 2018;15(1):13. doi:10.1186/s12976-018-  
453 0085-x
- 454 43. Ferguson N, Anderson R, Gupta S. The effect of antibody-dependent enhancement  
455 on the transmission dynamics and persistence of multiple-strain pathogens. *Proc*  
456 *Natl Acad Sci*. 1999;96(2):790-4. doi:10.1073/pnas.96.2.790.
- 457 44. Ferguson N, Andreasen V. The influence of different forms of cross-protective  
458 immunity on the population dynamics of antigenetically diverse populations.  
459 Castillo-Chavez C, Blower S, Kirschner D, van den Driessche P, Yakubu A (Eds.),  
460 *Mathematical Approaches for Emerging and Reemerging Infectious Diseases:*  
461 *Models, Methods and Theory*. IMA Volumes Mathematics and its Applications,  
462 vol. 126, Kluwer Academic Publishers, New York. 2002;157-169.
- 463 45. Kawaguchi I, Sasaki A, Boots M. Why are dengue virus serotypes so distantly  
464 related? Enhancement and limiting serotype similarity between dengue virus  
465 strains. *Proc Biol Sci*. 2003;270(1530):2241-7. doi:10.1098/rspb.2003.2440
- 466 46. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N. The effect of  
467 control strategies to reduce social mixing on outcomes of the COVID-19 epidemic  
468 in Wuhan, China: a modelling study. *Lancet Public Health*. 2020;e261-e270.  
469 doi:10.1016/S2468-2667(20)30073-6
- 470 47. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using  
471 contact surveys and demographic data. *PLoS Comput Biol*. 2017;13(9):e1005697.  
472 doi:10.1371/journal.pcbi.1005697
- 473 48. Diekmann O, Heesterbeek JAP. *Mathematical epidemiology of infectious diseases.*  
474 *Model building, analysis and interpretation*. 2000;Chichester (UK):Wiley.
- 475 49. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social  
476 Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. *PLoS*  
477 *Med*. 2008;5(3):e74. doi:10.1371/journal.pmed.0050074
- 478 50. United Nations, 2020. Annual Population Indicators in Standard Projections.  
479 Available at <https://population.un.org/wpp/Download/Standard/Interpolated/>.  
480 (Accessed 13th May 2020)


481

482

483 **Figures**

484

485 Figure 1: The age distribution of mortality by COVID-19 in Italy reported on 13th May  
486 2020, Japan reported on 7th May 2020, and Spain reported on 12th May 2020. Circle,  
487 square, and “+” denote Italy, Japan, and Spain.




488

489

490


491 Figure 2: The sensitivity of (a) age-dependency of susceptibility and (b) transmission  
492 coefficient  $\beta$  against age distribution of mortality when age-independent mortality was  
493 assumed. In panel (a), all parameters except the exponent parameter  $\varphi$ , describing the  
494 variation of susceptibility among age groups, were fixed and parameterized as  $R_0 = 2.9$   
495 in the setting for Spain. In panel (b), all parameters parameterized as the setting for  
496 Spain ( $\varphi=12.3$ ) except were fixed except transmission coefficient  $\beta$ .



497  
498




499 Figure 3: The sensitivity of transmission coefficient  $\beta$  against age distribution of  
500 mortality when it was assumed that age-dependent mortality was proportional to cCFR  
501 per age group. All parameters were fixed and parameterized as the setting for Spain  
502 except the transmission coefficient  $\beta$ .




503  
504

505 Figure 4: The estimate of exponent parameter  $\rho$  describing the variation of  
506 susceptibility among age groups assuming that mortality rate does not depend on age.  
507 True and broken lines represent the maximum likelihood estimates and 95% confidence  
508 intervals, respectively.



509  
510  
511

512 Figure 5: The estimate of exponent parameter  $\varphi$  describing the variation of  
513 susceptibility among age groups assuming that mortality rate does not depend on age  
514 and the fraction of infections that becomes symptomatic among all COVID-19 cases is  
515 0.25. True and broken lines represent the maximum likelihood estimates and 95%  
516 confidence intervals, respectively.




517

518

519

520 Figure 6: The estimate of exponent parameter  $\varphi$  describing the variation of  
521 susceptibility among age groups assuming that mortality rate does not depend on age  
522 and the fraction of infections that becomes symptomatic among all COVID-19 cases is  
523 0.5. True and broken lines represent the maximum likelihood estimates and 95%  
524 confidence intervals, respectively.




525

526

527

528 Figure 7: The estimate of exponent parameter  $\varphi$  describing the variation of  
529 susceptibility among age groups assuming that mortality rate does not depend on age  
530 and the fraction of infections that becomes symptomatic among all COVID-19 cases is  
531 0.05. True and broken lines represent the maximum likelihood estimates and 95%  
532 confidence intervals, respectively.



533

534